Iloprost-release system for preventing delayed healing in patients with a musculoskeletal injury

Ref. No.: CH833

Background
Musculoskeletal injuries are often the result from accidents and encompass bone fractures, torn or otherwise damaged muscles or ruptured tendons. In Germany, the number of bone fracture incidents is estimated to be 1.6 million per year. Delayed or incomplete bone fracture healing can be observed in approximately 5-10% of patients following a fracture of the long bones. In normal healing patients the regenerative process starts with an initial inflammatory phase in which immune cells invade the fracture site and accessory cells are recruited, which is displaced by an anti-inflammatory phase after 24-36 hours after injury. A prolonged pro-inflammatory reaction due to a lack or damped anti-inflammatory phase negatively impact the healing process and is assumed to be the cause for delayed fracture healing.

Technology
We offer the use of Iloprost as an anti-inflammatory agent for the treatment of a patient with a musculoskeletal injury and with risk for delayed bone/muscle healing, wherein the first initial dose is administered or released not before 24 hours after musculoskeletal injury (best between 3 to 4 days after injury). Iloprost can be administered in combination with a biodegradable polymer such as fibrin to build a release system which can be administered during surgery. Alternatively, the drug can be injected or administered via an implant. By administering Iloprost, the prolonged pro-inflammatory phase in delayed healing patients could be stopped timely and anti-inflammatory processes can be supported. In a osteotomy mouse model (fracture performed on the left femur), a gel-based release system containing Iloprost, Fibrinogen and Thrombin-S solution was applied in the fracture region. Iloprost-release-system treated mice showed a better femur fracture healing 21 days after fracture than control mice which received only the release system.

Benefits
- Novel therapeutic approach for preventing delayed bone or muscle healing in risk patients with musculoskeletal injuries
- Optimizing drug exposition time by using release system

Application
Prevention or treatment of delayed bone fracture / muscle healing in patients with risk for delayed healing after musculoskeletal injury

Commercial Opportunity
Searching for a licensing or developing partner

Key words
Iloprost, Prostacyclin, musculoskeletal injury, delayed bone healing, delayed muscle healing, release system, immunomodulation

Developmental Status
first patient in, in vivo

IP Status
EP patent application (08/2017)
PCT patent application (08/2018)
Granted EP patent

Patent Owner
Charité – Universitätsmedizin Berlin

Contact
Dr. Bettina Büttner
Senior Technology Manager
Tel.: +49 30 450 570 874
Fax: +49 30 450 7570 964
Bettina.Buettner@charite.de
http://technologietransfer.charite.de
www.bihealth.org/de/CBI